Compounded Semaglutide

Deep dive

Compounded Semaglutide: complete reference

Compounded semaglutide is a custom-prepared formulation of semaglutide active pharmaceutical ingredient (API) that is NOT a finished FDA-approved product. Prepared by state-licensed 503A pharmacies (per-patient prescriptions) or 503B outsourcing facilities (larger batches), compounded semaglutide uses the same molecule found in FDA-approved Wegovy/Ozempic/Rybelsus but combined with carrier vehicles or additional ingredients (B12, glycerol, etc.) by the compounding pharmacy. The FDA does not review or approve specific compounded formulations — only the underlying API is FDA-regulated. Compounded semaglutide expanded dramatically during the 2023-2024 FDA shortage list, which created a legal basis for mass compounding under 503A rules. The FDA resolved the semaglutide shortage in February 2025, narrowing the legal basis. In 2026, FDA enforcement actions against compounding pharmacies + Hims's exit from the category signaled industry contraction. Cost remains attractive ($129-300/month vs $998-1,349 brand) but with regulatory uncertainty + variable quality between pharmacies. Patients should verify state pharmacy license + PCAB accreditation + avoid "semaglutide sodium" (salt form FDA flagged as unapproved).

In practice

A 503A pharmacy receives semaglutide API from an FDA-registered supplier, combines it with bacteriostatic water in vials, and dispenses to your prescriber's patient — that's compounded semaglutide.

Clinical context

Compounded GLP-1s are legal но NOT FDA-approved as finished products. Quality varies between pharmacies. Cost vs oversight trade-off.